Skip to main content

Table 2 Main side effects in the two cohorts of patients

From: High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

Cohort Toxicity G3-G4   Toxicity G1-G2
  Neutropenia Thrombopenia Anemia Others   Neutropenia Thrombopenia Anemia Others
Cohort A Schedule 1,8,28 1/7 pts 3/7 pts 0/7 pts 0/7   4/7 4/7 4/7 4/7 (1 transaminase increasing; 3 nausea-vomiting)
Cohort B Schedule 1, 21 0/7 pts 1/7 pts 0/7 pts 0/7   6/7 5/7 5/7 5/7 (1 asthenia; 4 nausea-vomiting)